Evidence map›Paper›PMID 25550201›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2015

AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?

Ziad Mallat, Alan Daugherty

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Pharmacologic Management of Aneurysms.Circulation research · 2019
    Review
  4. Therapies for Thoracic Aortic Aneurysms and Acute Aortic Dissections.Arteriosclerosis, thrombosis, and vascular biology · 2019
    Review
  5. Review
  6. Review
  7. TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.Cold Spring Harbor perspectives in biology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Ziad MallatFrom the Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, United Kingdom (Z.M.); and Saha Cardiovascular Research Center, University of Kentucky, Lexington (A.D.) zm255@medschl.cam.ac.uk Alan.Daugherty@uky.edu.
Alan DaughertyFrom the Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, United Kingdom (Z.M.); and Saha Cardiovascular Research Center, University of Kentucky, Lexington (A.D.).
University of Kentucky · US

Funding

Mechanisms of thoracic aortic aneurysmsR01HL107319 · NHLBI · UNIVERSITY OF KENTUCKY · PI DAUGHERTY, ALAN · 2012 to 2015
$2.1M
British Heart FoundationNHLBI NIH HHS HL107319NHLBI NIH HHS R01 HL107319
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adrenergic beta-AntagonistsAngiotensin II Type 1 Receptor BlockersAnimalsAortaAortic AneurysmDilatation, PathologicDisease Models, AnimalDose-Response Relationship, DrugHemodynamicsHumansMarfan SyndromeReceptor, Angiotensin, Type 1Renin-Angiotensin SystemSignal TransductionTranslational Research, BiomedicalTreatment OutcomeAdrenergic beta-AntagonistsAGTR1 protein, humanAngiotensin II Type 1 Receptor BlockersReceptor, Angiotensin, Type 1

Identifiers

PMID25550201
PMCPMC4304993
OpenAlexW2095775932

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.